Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Clinical Pearls for Treating MPN and MF

March 7th 2022

The panel concludes this discussion with clinical pearls they would like to share with colleagues that treat MPN and MF.

Unmet Needs and Potential Advances in MPN and MF

March 7th 2022

A group of experts share unmet needs in the treatment of MPN and MF while providing information about potential advances that could impact treatment in the future.

The Clinical Course for MF and Changing Therapies

March 7th 2022

Dr Fleischman explains the clinical course she would take with MF treatment and what it would take to change therapies.

NCCN Recommends Ropeginterferon Alfa-2b in Clinical Practice Guidelines Update

March 3rd 2022

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b as a recommended treatment option for adult patients with polycythemia vera.

Dr. Mesa on the FDA Approval of Pacritinib in Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

FDA Approves Pacritinib for Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

The FDA has granted an accelerated approval to pacritinib (Vonjo) for the treatment of select adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Monitoring Patients Being Treated for MF

February 28th 2022

Dr Oh lists the ways MF can and should be monitored.

Sequencing MF Therapies and Novel Combinations

February 28th 2022

The panel relays how they would sequence MF therapies, as well as the novel combination therapies that can be used.

Selecting a Therapy for Patients With MF

February 21st 2022

A panel of experts share how they select between treatment options for patients with MF.

More Upfront Therapy Options for MF

February 21st 2022

More upfront therapy options for the MF treatment landscape are discussed, including the safety profiles of these drugs.

Pelabresib Monotherapy Shows Benefit in JAK Inhibitor–Naïve Advanced Myelofibrosis

February 17th 2022

Marina Kremyanskaya, MD, PhD, discusses the safety and efficacy of pelabresib in patients with myelofibrosis, additional data from the MANIFEST trial, and other efforts investigating the agent in this disease.

Determining Treatment for MF And Upfront Therapy Options

February 14th 2022

A group of experts explain how to determine treatment for each patient with MF, as well as upfront therapy options.

More About MF Prognosis, Biomarkers, and Treatment

February 14th 2022

The panel continues the MF prognosis discussion while also discussing biomarkers and treatment for the disease.

MF Prognosis and Common Risks

February 7th 2022

Drs Shammo and Mesa explain the MF prognosis and possible risk factors.

A Myelofibrosis Diagnosis

February 7th 2022

Dr Fleischman provides details about myelofibrosis (MF) and what factors are considered with a diagnosis.

Orca-T Graft Improves Outcomes in Myelofibrosis Following Allogeneic Stem Cell Transplant

February 4th 2022

Arpita Gandhi, MD, discusses a subgroup analysis of patients with myelofibrosis who received Orca-T and how this type of therapy could be a game-changer for this patient population.

EU Panel Recommends Avapritinib for Advanced Systemic Mastocytosis

January 31st 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended to expand the current indication for avapritinib to include single-agent use in patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, or mast cell leukemia.

Dr. Verstovsek on the Tolerability of Momelotinib in Myelofibrosis

January 28th 2022

Srdan Verstovsek, MD, PhD, discusses the tolerability of momelotinib in myelofibrosis.

Dr. Gerds on Emerging Agents in Myelofibrosis

January 27th 2022

Aaron T. Gerds, MD, MS, discusses emerging agents in myelofibrosis.

FDA Places Partial Clinical Hold on Trials Examining Magrolimab Plus Azacitidine in MDS, AML, and Myeloid Malignancies

January 27th 2022

The FDA has placed a partial clinical hold on clinical trials evaluating the combination of magrolimab and azacitidine after an apparent imbalance in investigator-reported, suspected unexpected serious adverse reactions observed between study arms.